| ||
Agenda
Cell and Molecular Biology Lecture Hall (CMB)Berzelius väg 21 – Karolinska Institutet Solna Campus[click for map on Google]
|
8:30 | Arrival, coffee and get-together |
8:45 | Welcome and introduction about ULTRA-DD Michael Sundstrom (Karolinska) |
9:00 | The importance of jointly funded translational medicine IMI projects |
9:15 | Target selection and prioritization Julian Knight et al. (Oxford) |
9:45 | Converting prioritized targets into protein samples and antibody research tools Nicola Burgess-Brown (Oxford) and Susanne Gräslund (Karolinska) et al. |
10:15 | Predictive cell-based assays as a foundation for research tool identification and generation Gillian Farnie, Kilian Huber, Oleg Fedorov (Oxford) et al. |
10:45 | Coffee Break |
11:00 | Shedding light on protein structure and function Katharina Duerr, Liz Carpenter, Frank von Delft (Oxford) and Matthias Gstaiger (ETH Zurich) et al. |
11:30 | Generating high quality chemical probes for target validation Paul Brennan (Oxford) et al. |
12:00 | Better translational assays based on patient material Louise Berg (Karolinska), Fiona McCann (Oxford) et al. |
12:00 | Maximinsing impact: communication of results and creating research networks Brian Marsden, Wen Hwa Lee (Oxford) et al. |
13:00 | Lunch and Networking |
Showcase on Collaborative Initiatives with ULTRA-DD | |
14:00 | Boehringer-Ingelheim’s approach to Open Science Adrian Carter (Corporate VP and Global Head Discovery Research Coordination) |
14:20 | Research and clinical aspects of IBD
Ola Winqvist (Professor of cellular immunotherapy, KI) |
14:40 | Drug Development and Discovery Platform at Science for Life Laboratory at Karolinska Institutet Per Arvidsson (Exec. Director Drug Discovery & Development, Science for Life) |
15:00 | The IMI European Lead Factory (ELF) Jon de Vlieger (Business developer Lygature/ ELF) |
15:20 | Coffee Break |
15:30 | The merits of Open Science – Panel Discussion |
16:00 | Wrap-up and end of meeting |